Recognising colchicine role in cardiovascular disease prevention
Early initiation of low-dose colchicine after MI reduces the risk of ischaemic cardiovascular events - benefits emerge early and continue to accrue
You will learn:
• Gout and hyperuricaemia have been linked to an increased risk of coronary artery disease (CAD), heart failure and cardiovascular mortality (1)
• Colchicine, as first-line therapy in both gout and pericarditis, has multiple anti-inflammatory actions
• It is timeous for clinicians to review the latest results of colchicine clinical trials in CAD and myocardial infarction (MI) for consideration for very high-risk patients and for adoption in their daily practice
• The recent 2021 European Society of Cardiology (ESC) guidelines on cardiovascular disease prevention in clinical practice provides a recommended framework for the use of colchicine.